This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
Randomised controlled trial. The study was single centred. Patients were allocated to the 2 groups using a table of random numbers. Blinding was not possible in the treatment and is not mentioned in the measurement or interpretation of results. Strategy A treatment continued for 16 weeks and follow up results are given for both strategies for 20 months after that. Reasons for loss to follow up were not given but it seems to have been high.
Analysis of effectiveness
The analysis was based on treatment completers only. Primary health outcomes were the seroconversion rate expressed as a percentage, the proportion of patients who elicited anti-HBs titres (seroprotection) and the levels of anti-HBs expressed as geometric mean titres and 95% confidence intervals. Groups were comparable in age, sex distribution, body weight and underlying nephropathies. There was no statistical difference in the proportion of diabetic patients, the median duration of chronic hemodialysis (HD) treatment or any other clinical characteristics but there was a significant difference in the numbers who had received blood transfusions before the start of the programme.
Effectiveness results
One month after strategy A treatment finished, 100% (25/25) of patients in the id group had developed seroconversion and 48% (12/25) in the im group (p = 0.008). 96% (24/25) showed seroprotection in the id group and 40% (10/25) in the im group (p = 0.001). The levels of anti-HBs expressed as geometric mean titres and 95% confidence intervals were 100 (44-187) for id and 26 (14-52) for im (p = 0.018). Twelve months after treatment finished differences were not significant. 57% (8/14) of patients in the id group had developed seroconversion and 14% (1/7) in the im group (p = 0.158). 59% (7/14) showed seroprotection in the id group and 0% (0/7) in the im group (p=0.072). Twenty months after treatment differences were not significant.54% (7/13) of patients in the id group had developed seroconversion and 0% (0/7) in the im group (p = 0.055). 30% (4/13) showed seroprotection in the id group and 0% (0/7) in the im group (p=0.2). Side effects were self reported by patients but were minor and temporary.
Clinical conclusions
Hepatitis B vaccine, administered intradermally, shows higher immunogenicity compared to the same vaccine administered intramuscularly over a 20 month follow up period.
Outcomes assessed in the review
A review supplied other effectiveness information: the seroprotection rate expressed as a percentage of non-responder patients in the 2 comparator strategies (Strategy C, intramuscular vaccination using thymopentin and HB vaccine, Strategy D, intramuscular vaccination using interleukin-2 and HB vaccine).
Study designs and other criteria for inclusion in the review
Not stated.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
None are described.
Methods used to judge relevance and validity, and for extracting data
NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination
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Number of primary studies included
Two primary studies were used.
Methods of combining primary studies
Studies were not combined. Each provided a separate comparator.
Investigation of differences between primary studies
Differences were not investigated.
Results of the review
In strategy C, intramuscular vaccination using thymopentin and HB vaccine, a seroprotection rate of 86% was achieved.
In strategy D, intramuscular vaccination using interleukin-2 and HB vaccine, a seroprotection rate of 56% was achieved.
Measure of benefits used in the economic analysis
No single measure of benefit was produced by the authors.
Direct costs
For the clinical trial of strategies A and B, costs of recombinant B vaccine only were included. The price of a 20micrograms vial paid by the hospital at the time of the study was given and used to calculate the cost of drugs per patient. Labour costs were not included because, as the authors stated, dialysis patients receive intense care and undergo regular follow up in any case. Labour resources used would not otherwise have been the same for both strategies. Costs of storage/refrigeration and of needles or other equipment were not given. For the other comparators the price that the hospital would have paid for drugs at the time of the study is used to calculate a cost per patient. Again only costs of drugs are given. The viewpoint is that of the hospital.
